Intraperitoneal Chemotherapy for Stage III Ovarian Cancer Using the Gynecologic Oncology Group Protocol 172 Intraperitoneal Regimen: Effect of Supportive Care Using Aprepitant and Pegfilgrastim on Treatment Completion Rate

Guile, Matthew W.; Horne, Amy; Thompson, Sharon; Gardner, Ginger J.; Giuntoli, Robert L.; Armstrong, Deborah K.; Bristow, Robert E.

doi:10.3816/coc.2008.n.007

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Intraperitoneal Chemotherapy for Stage III Ovarian Cancer Using the Gynecologic Oncology Group Protocol 172 Intraperitoneal Regimen: Effect of Supportive Care Using Aprepitant and Pegfilgrastim on Treatment Completion Rate

Cited by 4 publications

References 20 publications

Does Intraperitoneal Therapy for Ovarian Cancer Have a Future?

Does Intraperitoneal Therapy for Ovarian Cancer Have a Future?

Intraperitoneal Chemotherapy: Practicality Versus Theory

Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer

Contact Info

Product

Resources

About